ImmunoPrecise Antibodies (IPA) Competitors $0.44 +0.01 (+2.55%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$0.40 -0.04 (-8.65%) As of 04/17/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. IKNA, PYXS, KRON, GANX, ONCY, VRCA, VNRX, PMVP, ICCC, and STROShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Ikena Oncology (IKNA), Pyxis Oncology (PYXS), Kronos Bio (KRON), Gain Therapeutics (GANX), Oncolytics Biotech (ONCY), Verrica Pharmaceuticals (VRCA), VolitionRx (VNRX), PMV Pharmaceuticals (PMVP), ImmuCell (ICCC), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Ikena Oncology Pyxis Oncology Kronos Bio Gain Therapeutics Oncolytics Biotech Verrica Pharmaceuticals VolitionRx PMV Pharmaceuticals ImmuCell Sutro Biopharma ImmunoPrecise Antibodies (NASDAQ:IPA) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Do insiders and institutionals hold more shares of IPA or IKNA? 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are owned by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Comparatively, 5.9% of Ikena Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, IPA or IKNA? ImmunoPrecise Antibodies has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Does the MarketBeat Community prefer IPA or IKNA? Ikena Oncology received 15 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 93.75% of users gave ImmunoPrecise Antibodies an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote. CompanyUnderperformOutperformImmunoPrecise AntibodiesOutperform Votes1593.75% Underperform Votes16.25%Ikena OncologyOutperform Votes3058.82% Underperform Votes2141.18% Do analysts prefer IPA or IKNA? ImmunoPrecise Antibodies currently has a consensus price target of $4.00, indicating a potential upside of 813.45%. Ikena Oncology has a consensus price target of $3.00, indicating a potential upside of 170.27%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher probable upside, research analysts clearly believe ImmunoPrecise Antibodies is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is IPA or IKNA more profitable? Ikena Oncology has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -114.50%. Ikena Oncology's return on equity of -36.88% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets ImmunoPrecise Antibodies-114.50% -73.74% -42.68% Ikena Oncology N/A -36.88%-33.08% Does the media prefer IPA or IKNA? In the previous week, Ikena Oncology had 1 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 2 mentions for Ikena Oncology and 1 mentions for ImmunoPrecise Antibodies. Ikena Oncology's average media sentiment score of 1.56 beat ImmunoPrecise Antibodies' score of 1.00 indicating that Ikena Oncology is being referred to more favorably in the news media. Company Overall Sentiment ImmunoPrecise Antibodies Positive Ikena Oncology Very Positive Which has better earnings and valuation, IPA or IKNA? ImmunoPrecise Antibodies has higher revenue and earnings than Ikena Oncology. Ikena Oncology is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunoPrecise Antibodies$24.00M0.57-$20.13M-$1.16-0.38Ikena Oncology$659K81.28-$68.17M-$1.01-1.10 SummaryIkena Oncology beats ImmunoPrecise Antibodies on 10 of the 18 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.60M$6.46B$5.31B$7.35BDividend YieldN/A3.22%5.47%4.31%P/E Ratio-0.566.9521.9417.82Price / Sales0.57231.01380.9497.71Price / CashN/A65.6738.3134.64Price / Book0.475.936.453.98Net Income-$20.13M$143.22M$3.22B$247.81M7 Day Performance1.53%4.28%5.85%3.19%1 Month Performance-1.93%-13.11%-9.58%-7.70%1 Year Performance-65.25%-8.51%11.85%1.49% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies2.7422 of 5 stars$0.44+2.6%$4.00+813.5%-65.2%$13.60M$24.00M-0.5680Short Interest ↓Positive NewsGap DownIKNAIkena Oncology3.2474 of 5 stars$1.17+6.4%$3.00+156.4%-16.5%$56.46M$659,000.00-0.9570Short Interest ↓News CoverageGap DownPYXSPyxis Oncology1.1636 of 5 stars$0.92-4.6%$9.20+905.5%-76.8%$56.36M$16.15M-0.8960News CoverageKRONKronos Bio3.3638 of 5 stars$0.86+9.9%$1.63+89.5%-12.1%$52.29M$9.85M-0.60100Short Interest ↓Gap UpGANXGain Therapeutics2.3678 of 5 stars$1.87+11.1%$8.20+338.5%-43.4%$51.96M$50,000.00-1.7020Gap UpONCYOncolytics Biotech1.644 of 5 stars$0.59-5.3%$4.33+634.5%-47.1%$50.99MN/A-2.1930VRCAVerrica Pharmaceuticals3.4787 of 5 stars$0.55+14.2%$9.50+1,618.2%-93.0%$50.75M$7.57M-0.3040Short Interest ↑Gap DownVNRXVolitionRx1.2629 of 5 stars$0.50+2.9%$3.33+563.7%-21.4%$50.60M$1.23M-1.3980PMVPPMV Pharmaceuticals2.3577 of 5 stars$0.95+9.2%$5.67+495.2%-36.6%$49.44MN/A-0.9550Positive NewsGap UpICCCImmuCell0.1014 of 5 stars$5.50+1.7%N/A+9.6%$49.41M$26.49M-11.0070High Trading VolumeSTROSutro Biopharma3.8892 of 5 stars$0.60-0.9%$6.63+1,009.9%-85.5%$49.22M$62.04M-0.37240 Related Companies and Tools Related Companies Ikena Oncology Alternatives Pyxis Oncology Alternatives Kronos Bio Alternatives Gain Therapeutics Alternatives Oncolytics Biotech Alternatives Verrica Pharmaceuticals Alternatives VolitionRx Alternatives PMV Pharmaceuticals Alternatives ImmuCell Alternatives Sutro Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IPA Stock Free IPA Stock Alerts